Cardiovascular Risk Associated With Concurrent Proton Pump Inhibitor and Clopidogrel Therapy: Is It Explained by Interaction With CYP2C19 Genotype?

被引：0
|
作者：
Carlquist, John F. [1 ]
Horne, Benjamin D. [1 ]
Huntinghouse, John A. [1 ]
Park, James J. [1 ]
Mower, Chrissa P. [1 ]
Schaefer, Katie [1 ]
Hall, Nathaniel L. [1 ]
Mathews, Katy D. [1 ]
May, Heidi T. [1 ]
Muhlestein, Joseph B. [1 ]
Anderson, Jeffrey L. [1 ]
机构：
[1] Univ Utah, Intermt Med Ctr, Murray, UT USA
来源：
CIRCULATION | 2009年 / 120卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S599 / S599
页数：1
相关论文
共 50 条
  • [21] CYP2C19 genotype is a useful marker of optimal dose of a proton pump inhibitor in the maintenance therapy of symptomatic gastroesophageal reflux diseases
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Kodaira, Chise
    Nishino, Masafumi
    Yamade, Mihoko
    Ikuma, Mutsuhiro
    Kimura, Michio
    Hishida, Akira
    Ishizaki, Takashi
    GASTROENTEROLOGY, 2008, 134 (04) : A172 - A173
  • [22] Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction
    J P Depta
    P A Lenzini
    D E Lanfear
    T Y Wang
    J A Spertus
    R G Bach
    S Cresci
    The Pharmacogenomics Journal, 2015, 15 : 20 - 25
  • [23] CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects
    Sakai, T
    Aoyama, N
    Kita, T
    Sakaeda, T
    Nishiguchi, K
    Nishitora, Y
    Hohda, T
    Sirasaka, D
    Tamura, T
    Tanigawara, Y
    Kasuga, M
    Okumura, K
    PHARMACEUTICAL RESEARCH, 2001, 18 (06) : 721 - 727
  • [24] Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction
    Depta, J. P.
    Lenzini, P. A.
    Lanfear, D. E.
    Wang, T. Y.
    Spertus, J. A.
    Bach, R. G.
    Cresci, S.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (01): : 20 - 25
  • [25] CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects
    Toshiyuki Sakai
    Nobuo Aoyama
    Tomoko Kita
    Toshiyuki Sakaeda
    Kohshi Nishiguchi
    Yukari Nishitora
    Takashi Hohda
    Daisuke Sirasaka
    Takao Tamura
    Yusuke Tanigawara
    Masato Kasuga
    Katsuhiko Okumura
    Pharmaceutical Research, 2001, 18 : 721 - 727
  • [26] Clopidogrel, CYP2C19 and Proton Pump Inhibitors: What We Know and What it Means
    Hariharan, Sudharshan
    Southworth, Mary Ross
    Madabushi, Rajanikanth
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (08): : 884 - 888
  • [27] CYP2C19 Genotype and Cardiovascular Events Reply
    Nissen, Steven E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1485 - 1485
  • [28] Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
    Westergaard, Niels
    Tarnow, Lise
    Vermehren, Charlotte
    METABOLITES, 2021, 11 (02) : 1 - 11
  • [29] EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING
    Le, T.
    Nguyen, A.
    Winget, M.
    Kulick, N.
    Venkatesh, S.
    Rossi, J.
    Stouffer, G.
    Lee, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S23 - S24
  • [30] EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING
    Le, T.
    Nguyen, A.
    Winget, M.
    Kulick, N.
    Venkatesh, S.
    Rossi, J.
    Stouffer, G.
    Lee, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S89 - S89
12345